almey: yes Perseis being dumped was not a surprise.
It would have been nice to been given a solid reason, but presumably Noble's repeat of the xenograft trials showed no effect. Alternatively it could purely be because of the decision to focus on 2566/2591 but if there were good results lurking in there you don't imagine the company holding them back.
17 FXS trial enrolments is about what I expected, interesting that they're rolling out 4 more trial centres and implying that the enrolment has been a bit slow so far. That does surprise me a bit as the FXS trial sites were in major urban areas closer to large populations (Houston's a big place but NY and Chicago are bigger). Maybe FXS is suffering from "trial fatigue".
Concussion trial waiting on government wheels to turn.
All in all no surprises.
NEU Price at posting:
9.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)